These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 23979520)

  • 1. Combinatorial drug screening identifies synergistic co-targeting of Bruton's tyrosine kinase and the proteasome in mantle cell lymphoma.
    Axelrod M; Ou Z; Brett LK; Zhang L; Lopez ER; Tamayo AT; Gordon V; Ford RJ; Williams ME; Pham LV; Weber MJ; Wang ML
    Leukemia; 2014 Feb; 28(2):407-10. PubMed ID: 23979520
    [No Abstract]   [Full Text] [Related]  

  • 2. Impact of therapeutic inhibition of oncogenic cell signaling tyrosine kinase on cell metabolism: in vivo-detectable metabolic biomarkers of inhibition.
    Nath K; Gupta PK; Basappa J; Wang S; Sen N; Lobello C; Tomar JS; Shestov AA; Orlovskiy S; Arias-Mendoza F; Rauert-Wunderlich H; Nelson DS; Glickson JD; Wasik MA
    J Transl Med; 2024 Jul; 22(1):622. PubMed ID: 38965536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transformed mantle cell lymphoma with additional triple-hit genotypes can be resistant to a Bruton tyrosine kinase inhibitor.
    Yuan CT; Ma WL
    Blood; 2024 May; 143(20):2106. PubMed ID: 38753358
    [No Abstract]   [Full Text] [Related]  

  • 4. Bruton's Tyrosine Kinase Inhibition in Pemphigus: An Embattled Frontier.
    Payne AS; Manfredo Vieira S
    J Invest Dermatol; 2024 Aug; 144(8):1667-1670. PubMed ID: 38691069
    [No Abstract]   [Full Text] [Related]  

  • 5. Immune-depleted tumor microenvironment is associated with poor outcomes and BTK inhibitor resistance in mantle cell lymphoma.
    Jain P; Nomie K; Kotlov N; Segodin V; Hill H; Ok CY; Fetooh A; Kanagal-Shamanna R; Vega F; Bagaev A; Fowler N; Flowers CR; Wang M
    Blood Cancer J; 2023 Oct; 13(1):156. PubMed ID: 37821434
    [No Abstract]   [Full Text] [Related]  

  • 6. Localized upper extremity edema secondary to Bruton's tyrosine kinase inhibition.
    Leung BW; Fay CJ; Said JT; Sheets AR; Lian CG; Brown JR; Castillo JJ; Sarosiek S; Flynn C; LeBoeuf NR
    Leuk Lymphoma; 2023 Dec; 64(12):2047-2050. PubMed ID: 37671695
    [No Abstract]   [Full Text] [Related]  

  • 7. Unmet needs in relapsed/refractory mantle cell lymphoma after failure of covalent Bruton's tyrosine kinase inhibitors: An Italian scenario.
    Pinto A; Ladetto M; Martelli M; Visco C; Zaja F; Guardalben E; Zinzani PL
    Hematol Oncol; 2024 Jan; 42(1):e3246. PubMed ID: 38287533
    [No Abstract]   [Full Text] [Related]  

  • 8. Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells.
    Ma J; Lu P; Guo A; Cheng S; Zong H; Martin P; Coleman M; Wang YL
    Br J Haematol; 2014 Sep; 166(6):849-61. PubMed ID: 24957109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
    Byrd JC; Brown JR; O'Brien S; Barrientos JC; Kay NE; Reddy NM; Coutre S; Tam CS; Mulligan SP; Jaeger U; Devereux S; Barr PM; Furman RR; Kipps TJ; Cymbalista F; Pocock C; Thornton P; Caligaris-Cappio F; Robak T; Delgado J; Schuster SJ; Montillo M; Schuh A; de Vos S; Gill D; Bloor A; Dearden C; Moreno C; Jones JJ; Chu AD; Fardis M; McGreivy J; Clow F; James DF; Hillmen P;
    N Engl J Med; 2014 Jul; 371(3):213-23. PubMed ID: 24881631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4 Wild-type and CXCR4 WHIM mutated Waldenstrom macroglobulinaemia cells.
    Cao Y; Yang G; Hunter ZR; Liu X; Xu L; Chen J; Tsakmaklis N; Hatjiharissi E; Kanan S; Davids MS; Castillo JJ; Treon SP
    Br J Haematol; 2015 Jul; 170(1):134-8. PubMed ID: 25582069
    [No Abstract]   [Full Text] [Related]  

  • 11. Combination of ibrutinib with ABT-199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT and BCL2 pathways.
    Zhao X; Bodo J; Sun D; Durkin L; Lin J; Smith MR; Hsi ED
    Br J Haematol; 2015 Mar; 168(5):765-8. PubMed ID: 25284608
    [No Abstract]   [Full Text] [Related]  

  • 12. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.
    Burger JA; Keating MJ; Wierda WG; Hartmann E; Hoellenriegel J; Rosin NY; de Weerdt I; Jeyakumar G; Ferrajoli A; Cardenas-Turanzas M; Lerner S; Jorgensen JL; Nogueras-González GM; Zacharian G; Huang X; Kantarjian H; Garg N; Rosenwald A; O'Brien S
    Lancet Oncol; 2014 Sep; 15(10):1090-9. PubMed ID: 25150798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.
    Woyach JA; Furman RR; Liu TM; Ozer HG; Zapatka M; Ruppert AS; Xue L; Li DH; Steggerda SM; Versele M; Dave SS; Zhang J; Yilmaz AS; Jaglowski SM; Blum KA; Lozanski A; Lozanski G; James DF; Barrientos JC; Lichter P; Stilgenbauer S; Buggy JJ; Chang BY; Johnson AJ; Byrd JC
    N Engl J Med; 2014 Jun; 370(24):2286-94. PubMed ID: 24869598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 2 study of ibrutinib plus venetoclax in Japanese patients with relapsed/refractory mantle cell lymphoma.
    Goto H; Ito S; Kizaki M; Yamaguchi M; Fukuhara N; Kato K; Saito T; Terui Y; Okubo S; Soshin T; Zeng J; Honda H; Badawi M; Ross JA; Izutsu K
    Int J Clin Oncol; 2024 Feb; 29(2):232-240. PubMed ID: 38157190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PP2A modulation overcomes multidrug resistance in chronic lymphocytic leukemia via mPTP-dependent apoptosis.
    Jayappa KD; Tran B; Gordon VL; Morris C; Saha S; Farrington CC; O'Connor CM; Zawacki KP; Isaac KM; Kester M; Bender TP; Williams ME; Portell CA; Weber MJ; Narla G
    J Clin Invest; 2023 Jul; 133(13):. PubMed ID: 37166997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma.
    Portell CA; Wages NA; Kahl BS; Budde LE; Chen RW; Cohen JB; Varhegyi NE; Petroni GR; Williams ME
    Blood Adv; 2022 Mar; 6(5):1490-1498. PubMed ID: 34700344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extrinsic interactions in the microenvironment in vivo activate an antiapoptotic multidrug-resistant phenotype in CLL.
    Jayappa KD; Gordon VL; Morris CG; Wilson B; Shetty BD; Cios KJ; Arora PC; Isaac KM; Saha S; Bender TP; Williams ME; Portell CA; Weber MJ
    Blood Adv; 2021 Sep; 5(17):3497-3510. PubMed ID: 34432864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitors targeting Bruton's tyrosine kinase in cancers: drug development advances.
    Wen T; Wang J; Shi Y; Qian H; Liu P
    Leukemia; 2021 Feb; 35(2):312-332. PubMed ID: 33122850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ibrutinib Resistance Mechanisms and Treatment Strategies for B-Cell lymphomas.
    George B; Chowdhury SM; Hart A; Sircar A; Singh SK; Nath UK; Mamgain M; Singhal NK; Sehgal L; Jain N
    Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32455989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simultaneous kinase inhibition with ibrutinib and BCL2 inhibition with venetoclax offers a therapeutic strategy for acute myeloid leukemia.
    Eide CA; Kurtz SE; Kaempf A; Long N; Agarwal A; Tognon CE; Mori M; Druker BJ; Chang BH; Danilov AV; Tyner JW
    Leukemia; 2020 Sep; 34(9):2342-2353. PubMed ID: 32094466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.